Cargando…

The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis

There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakkunarajah, Suganija, Breadner, Daniel A., Zhang, Hanbo, Yamanaka, Ellen, Warner, Andrew, Welch, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535138/
https://www.ncbi.nlm.nih.gov/pubmed/34677260
http://dx.doi.org/10.3390/curroncol28050342
_version_ 1784587706440876032
author Lakkunarajah, Suganija
Breadner, Daniel A.
Zhang, Hanbo
Yamanaka, Ellen
Warner, Andrew
Welch, Stephen
author_facet Lakkunarajah, Suganija
Breadner, Daniel A.
Zhang, Hanbo
Yamanaka, Ellen
Warner, Andrew
Welch, Stephen
author_sort Lakkunarajah, Suganija
collection PubMed
description There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOLFOX had DFS rates of 76.9% and 71.2% at 3 and 5 years, respectively. OS rates were 86.4% and 76.7% at 3 and 5 years, respectively. Median RDI was 73.8% for capecitabine and 76.3% and 85.6% for the oxaliplatin and 5-FU components respectively. Based on a multivariate analysis in patients receiving FOLFOX, those with an oxaliplatin DI > 80% had improvements in DFS and OS compared to those with an oxaliplatin DI of ≤80%. Otherwise, there was no significant difference in DFS or OS when comparing patients who achieved an RDI or a DI of above versus below 80% in the patients receiving adjuvant chemotherapy for resected colon cancer.
format Online
Article
Text
id pubmed-8535138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85351382021-10-23 The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis Lakkunarajah, Suganija Breadner, Daniel A. Zhang, Hanbo Yamanaka, Ellen Warner, Andrew Welch, Stephen Curr Oncol Article There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOLFOX had DFS rates of 76.9% and 71.2% at 3 and 5 years, respectively. OS rates were 86.4% and 76.7% at 3 and 5 years, respectively. Median RDI was 73.8% for capecitabine and 76.3% and 85.6% for the oxaliplatin and 5-FU components respectively. Based on a multivariate analysis in patients receiving FOLFOX, those with an oxaliplatin DI > 80% had improvements in DFS and OS compared to those with an oxaliplatin DI of ≤80%. Otherwise, there was no significant difference in DFS or OS when comparing patients who achieved an RDI or a DI of above versus below 80% in the patients receiving adjuvant chemotherapy for resected colon cancer. MDPI 2021-10-09 /pmc/articles/PMC8535138/ /pubmed/34677260 http://dx.doi.org/10.3390/curroncol28050342 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lakkunarajah, Suganija
Breadner, Daniel A.
Zhang, Hanbo
Yamanaka, Ellen
Warner, Andrew
Welch, Stephen
The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
title The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
title_full The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
title_fullStr The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
title_full_unstemmed The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
title_short The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
title_sort influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535138/
https://www.ncbi.nlm.nih.gov/pubmed/34677260
http://dx.doi.org/10.3390/curroncol28050342
work_keys_str_mv AT lakkunarajahsuganija theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT breadnerdaniela theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT zhanghanbo theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT yamanakaellen theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT warnerandrew theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT welchstephen theinfluenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT lakkunarajahsuganija influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT breadnerdaniela influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT zhanghanbo influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT yamanakaellen influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT warnerandrew influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis
AT welchstephen influenceofadjuvantchemotherapydoseintensityonfiveyearoutcomesinresectedcoloncancerasinglecentreretrospectiveanalysis